Novo Nordisk is investing $4.1 billion to expand its U.S. manufacturing capacity to address the growing demand for its highly sought-after weight-loss-related drugs. The Danish pharmaceutical manufacturer will also boost its current production investment this year to$6.8 billion, up significantly from $3.9 billion in 2023. With the funds, Novo Nordisk said it plans to add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, which will essentially double t ...